Haiyong Wang

List of Publications by Year in Descending Order

48 papers	**370** citations	**10** h-index	**17** g-index
52 ext. papers	**498** ext. citations	**3.6** avg, IF	**3.96** L-index

#	Paper	IF	Citations
48	Genomic Variations and Immune-Related Features of TMB, PD-L1 Expression and CD8 T Cell Infiltration in Chinese Pulmonary Sarcomatoid Carcinoma.. *International Journal of General Medicine*, **2022**, 15, 4209-4220	2.3	0
47	Clinicopathological Difference and Survival Impact of Patients with c-SCLC and SCLC. *International Journal of General Medicine*, **2021**, 14, 6899-6906	2.3	0
46	A 5-Genomic Mutation Signature Can Predict the Survival for Patients With NSCLC Receiving Atezolizumab. *Frontiers in Immunology*, **2021**, 12, 606027	8.4	1
45	PDL1 high expression without TP53, KEAP1 and EPHA5 mutations could better predict survival for patients with NSCLC receiving atezolizumab. *Lung Cancer*, **2021**, 151, 76-83	5.9	5
44	A clinical variable-based nomogram could predict the survival for advanced NSCLC patients receiving second-line atezolizumab. *Cancer Medicine*, **2021**, 10, 6218-6226	4.8	1
43	Incorporating the Number of PLN into the AJCC Stage Could Better Predict the Survival for Patients with NSCLC: A Large Population-Based Study. *Journal of Oncology*, **2020**, 2020, 1087237	4.5	1
42	Patients With -Mutant NSCLC May Not Benefit From Immune Checkpoint Inhibitors: A Population-Based Study. *JTO Clinical and Research Reports*, **2020**, 1, 100006	1.4	3
41	CD44, a marker of cancer stem cells, is positively correlated with PD-L1 expression and immune cells infiltration in lung adenocarcinoma. *Cancer Cell International*, **2020**, 20, 583	6.4	11
40	KEAP1-NFE2L2-Mutant NSCLC and Immune Checkpoint Inhibitors: A Large Database Analysis. *Journal of Thoracic Oncology*, **2020**, 15, e85-e86	8.9	8
39	A Novel Nomogram including AJCC Stages Could Better Predict Survival for NSCLC Patients Who Underwent Surgery: A Large Population-Based Study. *Journal of Oncology*, **2020**, 2020, 7863984	4.5	3
38	A 5-Gene Signature Is Closely Related to Tumor Immune Microenvironment and Predicts the Prognosis of Patients with Non-Small Cell Lung Cancer. *BioMed Research International*, **2020**, 2020, 2147397	3	6
37	Radiotherapy may improve survival of ES-SCLC with distant metastasis only for patients with one metastatic site: A population-based study. *Oncology Letters*, **2020**, 19, 139-146	2.6	2
36	Tumor Primary Location May Affect Metastasis Pattern for Patients with Stage IV NSCLC: A Population-Based Study. *Journal of Oncology*, **2020**, 2020, 4784701	4.5	4
35	Duration of immunotherapy in patients with advanced lung adenocarcinoma with negative driver genes: case report and literature review. *Thoracic Cancer*, **2020**, 11, 3001-3006	3.2	2
34	TERT mutations correlate with higher TMB value and unique tumor microenvironment and may be a potential biomarker for anti-CTLA4 treatment. *Cancer Medicine*, **2020**, 9, 7151-7160	4.8	9
33	Including positive lymph node count in the AJCC N staging may be a better predictor of the prognosis of NSCLC patients, especially stage III patients: a large population-based study. *International Journal of Clinical Oncology*, **2019**, 24, 1359-1366	4.2	5
32	Application of prophylactic cranial irradiation in limited-stage small-cell lung cancer: which patients could benefit?. *Future Oncology*, **2019**, 15, 3237-3245	3.6	3

31	Poor survival of non-small-cell lung cancer patients with main bronchus tumor: a large population-based study. *Future Oncology*, **2019**, 15, 2819-2827	3.6	4
30	Circular RNA hsa_circ_0078602 may have potential as a prognostic biomarker for patients with hepatocellular carcinoma. *Oncology Letters*, **2019**, 17, 2091-2098	2.6	20
29	The prognostic analysis of different metastatic patterns in extensive-stage small-cell lung cancer patients: a large population-based study. *Future Oncology*, **2018**, 14, 1397-1407	3.6	19
28	Optimizing intrapleural bevacizumab dosing in non-small-cell lung cancer-mediated malignant pleural effusion: less is more. *Future Oncology*, **2018**, 14, 2131-2138	3.6	2
27	Screening differential circular RNA expression profiles reveal that hsa_circ_0128298 is a biomarker in the diagnosis and prognosis of hepatocellular carcinoma. *Cancer Management and Research*, **2018**, 10, 1275-1283	3.6	40
26	Great efficacy of bevacizumab plus erlotinib for leptomeningeal metastases from non-small cell lung cancer with initially positive EGFR mutation: a case report. *Cancer Biology and Therapy*, **2018**, 19, 1073-1077	4.6	3
25	Preoperative radiation may improve the outcomes of resectable IIIA/N2 non-small-cell lung cancer patients: A propensity score matching-based analysis from surveillance, epidemiology, and end results database. *Cancer Medicine*, **2018**, 7, 4354-4360	4.8	11
24	High level of programmed death ligand 1 (PD-L1) predicts longer survival in patients with resectable small cell lung cancer. *International Journal of Clinical and Experimental Pathology*, **2018**, 11, 2675-2682	1.4	3
23	A prognostic score model to determine which breast cancer patients with 1-3 positive lymph nodes after modified radical mastectomy should receive radiotherapy. *Oncotarget*, **2018**, 9, 385-393	3.3	
22	Young male breast cancer, a small crowd, the survival, and prognosis?: A population-based study. *Medicine (United States)*, **2018**, 97, e12686	1.8	1
21	Characteristics and survival difference of clinical tumor size 0 extensive-stage small cell lung cancer with different metastasis pattern. *Journal of Thoracic Disease*, **2018**, 10, 5414-5420	2.6	1
20	Circular RNA Hsa_Circ_0091579 Serves as a Diagnostic and Prognostic Marker for Hepatocellular Carcinoma. *Cellular Physiology and Biochemistry*, **2018**, 51, 290-300	3.9	30
19	Previous Radiotherapy Increases the Efficacy of IL-2 in Malignant Pleural Effusion: Potential Evidence of a Radio-Memory Effect?. *Frontiers in Immunology*, **2018**, 9, 2916	8.4	4
18	Total lymphocyte count, neutrophil-lymphocyte ratio, and platelet-lymphocyte ratio as prognostic factors in advanced non-small cell lung cancer with chemoradiotherapy. *Cancer Management and Research*, **2018**, 10, 6677-6683	3.6	17
17	Better efficacy of intrapleural infusion of bevacizumab with pemetrexed for malignant pleural effusion mediated from nonsquamous non-small cell lung cancer. *OncoTargets and Therapy*, **2018**, 11, 8421-8426	4.4	1
16	PLNR☐0% may be a benefit from PORT for patients with IIIA-N2 NSCLC: a large population-based study. *Cancer Management and Research*, **2018**, 10, 3561-3567	3.6	5
15	Surgical intervention may be a therapeutic option for NSCLC patients with AJCC stage IV: a large population-based study. *Cancer Management and Research*, **2018**, 10, 3219-3226	3.6	2
14	How many ELNs are optimal for breast cancer patients with more than three PLNs who underwent MRM? A large population-based study. *OncoTargets and Therapy*, **2018**, 11, 1005-1011	4.4	1

13	Male patients with resected IIIA-N2 non-small-cell lung cancer may benefit from postoperative radiotherapy: a population-based survival analysis. *Future Oncology*, **2018**, 14, 2371-2381	3.6	6
12	Postmastectomy radiation therapy for breast cancer patients with one to three positive lymph nodes: a propensity score matching analysis. *Future Oncology*, **2017**, 13, 1395-1404	3.6	4
11	Better survival in PMRT of female breast cancer patients with >5 negative lymph nodes: A population-based study. *Medicine (United States)*, **2017**, 96, e5998	1.8	6
10	Thoracic radiation therapy could give survival benefit to elderly patients with extensive-stage small-cell lung cancer. *Future Oncology*, **2017**, 13, 1149-1158	3.6	6
9	The prognosis analysis of different metastasis pattern in patients with different breast cancer subtypes: a SEER based study. *Oncotarget*, **2017**, 8, 26368-26379	3.3	40
8	Significant efficacy and well safety of apatinib in an advanced liver cancer patient: a case report and literature review. *Oncotarget*, **2017**, 8, 20510-20515	3.3	34
7	Greater efficacy of intracavitary infusion of bevacizumab compared to traditional local treatments for patients with malignant cavity serous effusion. *Oncotarget*, **2017**, 8, 35262-35271	3.3	4
6	Better cancer specific survival in young small cell lung cancer patients especially with AJCC stage III. *Oncotarget*, **2017**, 8, 34923-34934	3.3	10
5	The appropriate number of ELNs for lymph node negative breast cancer patients underwent MRM: a population-based study. *Oncotarget*, **2017**, 8, 65668-65676	3.3	3
4	Kinetic change of serum carcinoembryonic antigen can early predict progression in patients with metastatic non-small cell lung cancer during maintenance therapy with bevacizumab plus pemetrexed. *Oncotarget*, **2017**, 8, 74910-74916	3.3	
3	Risk factors of brain metastasis during the course of EGFR-TKIs therapy for patients with EGFR-mutated advanced lung adenocarcinoma. *Oncotarget*, **2016**, 7, 81906-81917	3.3	17
2	Should all breast cancer patients with four or more positive lymph nodes who underwent modified radical mastectomy be treated with postoperative radiotherapy? A population-based study. *Oncotarget*, **2016**, 7, 75492-75502	3.3	6
1	Efficacy of cisplatin/pemetrexed with bevacizumab to treat advanced lung adenocarcinoma with different drive genes: case report and literature review. *OncoTargets and Therapy*, **2016**, 9, 4639-44	4.4	6